EMA: Draft exenatide powder and solvent for prolonged-release suspension for injection, 2 mg, and powder and solvent for prolonged-release suspension for injection in pre-filled pen, 2 mg product-specific bioequivalence guidance
This document provides product-specific guidance on the demonstration of the bioequivalence of exenatide.
Posted on the EMA website on 1 August 2016
Comparta esta información, escoja su plataforma